Table 1.
Baseline parameters/demographics. Losartan is compared with combined control (lopinavir/ritonavir and placebo) and placebo only control. Statistically significant and ‘trend’ comparisons are in bold.
|
Treatment |
Combined control |
p | 95% CI |
Placebo only control |
p | 95% CI | |
|---|---|---|---|---|---|---|---|
| Losartan | Lopinavir/ritonavir and placebo | Placebo | |||||
| N | 9 | 5 | NA | NA | 3 | NA | NA |
| Age (mean) | 63.7 | 61.8 | 0.8 | −17.0153 to 13.2153 | 56.3 | 0.4 | −27.4633 to 12.6633 |
| Male (%) | 66.7 | 60.0 | 0.9 | −0.80986 to 0.94319 | 66.7 | NA | NA |
| Enrollment spring 2020 | 11.1 | 60 | 0.1 | −1.0732 to 0.0955 | 33.3 | 0.4 | −0.7557 to 0.3112 |
| Enrollment fall 2020 - winter 2021 | 77.8 | 20 | 0.2 | −0.2486 to 1.4042 | 33.3 | 0.4 | −0.6224 to 1.5113 |
| Enrollment spring 2021 | 11.1 | 20 | 0.7 | −0.50209 to 0.32431 | 33.3 | 0.4 | −0.7557 to 0.3112 |
| Caucasian ethnicity (%) | 100 | 100 | NA | NA | 100 | NA | NA |
| COSS (mean) | 3.6 | 4.0 | 0.5 | −0.7192 to 1.5192 | 3.7 | 0.9 | −1.2961 to 1.4961 |
| Symptoms duration, days (mean) | 9.3 | 7.4 | 0.3 | −6.0157 to 2.315 | 6.7 | 0.3 | −7.9688 to 2.8688 |
| Comorbidites (targeted) rate (mean) | 1.0 | 2.6 | 0.02 | 0.3255 to 2.8745 | 2.7 | 0.046 | 0.0392 to 3.3608 |
| Immunocompromised (%) | 22.2 | 60 | 0.3 | −1.0311 to 0.2755 | 66.7 | 0.2 | −1.1988 to 0.3099 |
| Chronic heart disease (%) | 22.2 | 80 | 0.1 | −1.2935 to 0.1379 | 66.7 | 0.2 | −1.1988 to 0.3099 |
| Chronic lung disease (%) | 33.3 | 60 | 0.5 | −0.9823 to 0.449 | 66.7 | 0.5 | −1.1768 to 0.5101 |
| Chronic kidney disease (%) | 0 | 0 | NA | NA | 0 | NA | NA |
| Chronic liver disease (%) | 0 | 0 | NA | NA | 0 | NA | NA |
| Diabetes (%) | 22.2 | 25 | 0.9 | −0.48384 to 0.52828 | 33.3 | 0.7 | −0.7644 to 0.5422 |
| Extreme obesity (%) | 0 | 50 | 0.03 | −0.962 to −0.038 | 50 | 0.03 | −0.962 to −0.038 |
| Charlson Score (mean) | 2.5 | 4.5 | 0.08 | −0.3196 to 4.3196 | 3.7 | 0.3 | −1.1366 to 3.5366 |
| qSOFA (mean) | 0.33 | 0.6 | 0.4 | −0.3585 to 0.8985 | 0.3 | 1 | −0.7680 to 0.7680 |
| BMI (mean) | 31.0 | 31.8 | 0.4 | −4.2764 to 9.2764 | 35.1 | 0.2 | −2.3076 to 10.5076 |
| Creatinine (mean) | 0.7 | 0.9 | 0.4 | −0.2508 to 0.5708 | 0.7 | 0.9 | −0.2127 to 0.2327 |
| Chest x-ray opacities (%) | 88.9 | 100 | 0.9 | −1.1646 to 0.9423 | 100 | 0.9 | −1.3621 to 1.1399 |
| Pneumonia severity index (PSI) (mean) | 54.9 | 59.3 | 0.5 | −41.3071 to 50.1071 | 60 | 0.8 | −40.4537 to 21.2537 |
| Treatment days (mean) | 9.6 | 13.3 | 0.3 | −3.5545 to 10.8545 | 13 | 0.4 | −5.1086 to 11.9086 |
| Treatment with corticosteroids (%) | 88.9 | 40 | 0.3 | −0.7949 to 0.2172 | 60 | 0.7 | −0.9706 to 1.415 |